Boston Scientific sat out most rounds of med tech M&A the past few years, but the device giant might be charting a different course in 2015. The company is reportedly close to buying Endo International's AMS medical device unit in a deal estimated at $2 billion.
Valeant may have inked a pact to buy Salix Pharmaceuticals for more than $10 billion. But that doesn't necessarily mean rival bids aren't on the way.
Outsourced product design specialist TE Connectivity will increase its focus on medical devices with its $190 million purchase of catheter player AdvancedCath.
Everybody sees something different when they look at Eli Lilly, which has recently dropped out of the top 10 pharma group. A number of analysts, some with good reason to shine up to CEO John Lechleiter, see a company that has hit bottom and is on the comeback trail, with new drug approvals to help bolster Lechleiter's bullish forecasts.
2014 is bound to go down as the year of med tech merger mania. FierceMedicalDevices compiles the year's 10 biggest medical device and diagnostic mergers.
Takeda's CEO-in-waiting, Christophe Weber, has included emerging markets, along with oncology and gastrointestinal medicines, as one of three areas of focus. He recently said he is ready to do some deals to capitalize on those areas, and now he has executed one that straddles two of those favorites.
Fresh from completing a $5 billion deal for NPS Pharma, Shire stopped to bag a small San Diego biotech, picking up Meritage Pharma and a Phase III-ready rare disease drug for $70 million upfront and a slate of unspecified milestones.
PTC Therapeutics is looking to get bought, Reuters ' sources say, betting that a larger company will covet its treatment for Duchenne muscular dystrophy enough to overlook a checkered history.
Medtronic has just disclosed that it bought Advanced Uro-Solutions in December 2014 for an undisclosed amount. In August 2013, the FDA cleared the startup's neurostimulation device, the Nuro System, to treat overactive bladder and its associated symptoms of urinary urgency, urinary frequency and urge incontinence.
It didn't take long for serial acquirer Valeant to jump back into the dealmaking saddle after failing to snag Allergan last year. Now, the Canadian pharma has inked its second agreement of the month--a $10.1 billion pickup of North Carolina's Salix Pharmaceuticals that will ring in as its largest deal ever.